Skip to main content Accessibility help
  • Print publication year: 2010
  • Online publication date: December 2010

25 - Oxymorphone extended-release

from Section 2 - Oral and Parenteral Opioid Analgesics


1. Endo Pharmaceuticals, 2009. Opana and Opana ER monograph. Endo Chadds Ford.
2. AdamsMP, AhdiehH. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy 2004;24(4):468–476.
3. PrommerE. Oxymorphone: a review. Support Care Cancer 2006;14:109–115.
4. InturrisiCE. Clinical pharmacology of opioids for pain. Clin J Pain 2002;18(4):S3–S13.
5.Micromedex® Healthcare Series, DrugDex® Evaluations. Thompson Healthcare. Accessed August 17, 2009.
6. AdamsM, PieniazekHJ, GammaitoniAR, AhdiehH. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 2005;45:337–345.
7. National Disease Therapeutic Index (NDTI). Accessed October 25, 2007.